

### **Part 8. The defensiveness of the Healthcare sector during covid-19 with John Wylie, Head of Healthcare**

#### **Video Transcript (May 2020)**

#### **John Wylie, Head of Healthcare Jennifer Herbert, Key Account Manager - Listed Funds**

**Jennifer Herbert:**

Hello and welcome to our investment insights series, Magellan Minutes, in which our investment team dissects the markets and takes a deeper look into sectors and stocks in our global portfolios. My name is Jennifer Herbert, Key Account Manager at Magellan, and over the next ten minutes, I'll be talking to Magellan's head of healthcare, John Wiley, about our current views on the healthcare sector. Thanks for joining us, John.

**John Wiley:**

Thanks, Jen. It's a real pleasure to chat today.

**Jennifer Herbert:**

John, how defensive has the healthcare sector proven to be in the current environment?

**John Wiley:**

Well, Jen, at Magellan, we segment our healthcare universe into three broad categories. The first is our globally diversified pharmaceutical bucket. The second is our healthcare infrastructure portfolio. And the third is our medical devices and specialty products franchise.

With respect to defensiveness in recent market conditions, demand for pharmaceutical products is highly inelastic. And what I mean by that is, you don't stop taking a life-saving therapy in the event of either a recession or, indeed, a healthcare crisis. Those therapies are non-negotiable and you'll continue to fill your prescriptions. In the recent market conditions we've also seen not only patients continue to fill their prescriptions, but also fill them a little bit in advance. We've also seen some hospitals build inventory in advance of the virus-induced healthcare crisis. So, the globally diversified pharmaceuticals have held up very well in the recent market environment.

The second and third segments that we spend our time on in the healthcare team have been rather more affected by the recent market conditions. With respect to our healthcare infrastructure portfolios, and what I'm thinking about there is our hospital-type investments, those assets have been materially impacted by a global shutdown in elective surgical procedures. And that shutdown is rather temporary in nature. These are procedures that must occur, but because they're not emergencies, it's possible to defer them. And given the fixed-cost structure of a lot of those healthcare infrastructure assets, that's had a rather meaningful impact on shorter-term earnings. And that's something that we're monitoring very carefully.

And then, I mentioned the third segment inside our healthcare universe where we're focused, and that's the medical-devices and specialty-product segment. That's been subject to many of the same adverse impacts as our healthcare infrastructure segment.

**Jennifer Herbert:**

The Magellan Global strategy has two key healthcare holdings, HCA Healthcare and Novartis. Let's address HCA first. We were watching the political situation in the US closely and then covid-19 hit. What's our view on HCA now?

**John Wiley:**

Well, you're spot on, Jen. Late last year, we became increasingly concerned about HCA's exposure to political risks in the run-up to the US election later this year. In response to that concern, we spent quite a bit of time in Washington trying to unpack the puts and takes on that risk as it pertained to HCA. In response to that diligence, we made a decision to materially reduce our HCA exposure late last year. And so, we've retained a much smaller HCA position in the global strategy coming into this crisis. And we continue to retain that position to date.

With respect to HCA's near-term earnings drivers, we're very, very comfortable looking through the short-term impact from the elected surgery deferral and the consequences for its earnings in the short term or short-to-medium term. But our key concern, with respect to our HCA holding, or the key risk we're managing, rather, is that in the US private insurers pay hospitals considerably more than government payers or other alternative payers. So, in the US, because your employer typically pays for your private health insurance,

if unemployment rises, then your ability to access private health insurance, and in turn HCA's ability to receive superior reimbursement from that private insurer relative to alternatives, could be compromised.

**Jennifer Herbert:**

That's interesting, John. How are you thinking about peak unemployment?

**John Wiley:**

We work closely with our macro team as we try and frame up some of those inputs to our individual company models. HCA, as I mentioned, is acutely exposed to unemployment. Because we don't have a great conviction with respect to the duration until peak unemployment, and indeed the duration of the subsequent unwind from peak unemployment, our response has been to run a whole load of different scenarios for HCA, such that we understand the impact on its profit and loss statement deeply under various scenarios.

And the output of that work was there are a number of scenarios where, at the current price, HCA is relatively attractively valued. And, of course, there is a stack of scenarios, even at the current price, which would make us far more concerned about our exposure to this particular investment. That said, given our current overlay with respect to our macroeconomic view, we feel we're being adequately compensated for the risk that we're bearing on this particular investment. But, given the acute sensitivity to this unemployment input, it's something that we're monitoring very, very closely.

**Jennifer Herbert:**

Now turning to Novartis, the pharmaceutical company; has Novartis proven to be as defensive as we would have hoped in the current environment?

**John Wiley:**

So, Jen, I think I touched on at the outset that demand for Novartis's products and big pharma in general has been particularly inelastic in this crisis, which has been a source of some comfort for us with respect to our Novartis exposure. The additional comfort for Novartis comes from the fact that it's uniquely diversified across six key therapeutic areas. So, some of those areas are more defensive than others. Novartis's primary exposures to oncology, immunology, and neuroscience have been a source of great comfort with respect to antibiotics exposure.

There is one therapeutic area for Novartis, which is its ophthalmology franchise. And that franchise has been significantly more disrupted than other parts of its business. Fortunately, that franchise only represents approximately 10% of their revenue, but the challenge for that particular franchise is, when you visit your optometrist, you're doing so to receive a therapy that's essential to retain your existing vision, but it's not necessary to conduct that procedure immediately. So, as economies have entered lockdown, because that procedure is deferrable in the short term, we've seen a material impact, and will see over the coming quarter a material impact on that particular slice of Novartis's business. But, as I said, its diversification across a whole load of different therapeutic areas allows us to look through some of that short-term pain in one particular therapeutic area.

That said, there are two risks that we're acutely focused on for Novartis. The first risk is Novartis has very recently brought a lot of interesting technology to the market that will improve the standard of care for a number of different conditions. And they've also recently acquired a number of interesting assets where they're shortly going to bring those drugs or therapeutics to market. And the dilemma it faces as economies have gone into lockdown is it's really hard for patients to go and visit their physicians. And it's also really hard for the physician to move the patient onto a better, highly efficacious standard of care without visiting them in person.

So, until patients can freely see their physicians, and that's conditional on the duration of the lockdown in many economies, it will be hard for Novartis to build the launch traction it needs on some of those recent drug approvals or recent acquisitions. It's important that Novartis execute on its launch profile for these recent drugs after a relatively short lockdown duration, hopefully. Because these drugs are important to bridge patent expiries that are going to occur down the track. So, the growth profile of those new launches is important to try and offset that inevitable patent duration at some point.

The second risk that Novartis is exposed to that we're monitoring carefully is Novartis has some exposure to exactly the same unemployment mix impact that I was talking about with respect to HCA. Fortunately for Novartis, its exposure to that adverse mix effect is far less material than it is for a business like HCA. And that relatively lower materiality comes from the fact that only 35% of Novartis's revenue is earned in the US. And indeed, their mix of revenue in the US we think is relatively favourable, certainly relative to a number of its competitors.

**Jennifer Herbert:**

Do you think the stock is fairly priced? And what do you see as the risks and opportunities?

**John Wiley:**

Well, Jen, I think I touched on a number of the risks that are on our mind for Novartis in our prior question. The key highlights for us, with respect to the Novartis investment thesis, is the comfort we derive from Novartis's diversification by therapeutic area, and also importantly, its diversification with respect to patent duration as well. And what those two things give us is they give us a lot more conviction that we're not exposing ourselves to binary scientific risks, which aren't easy to forecast with great accuracy consistently.

So, we have a set of relatively conservative assumptions for Novartis. And, on those assumptions, we have a view that the stock is currently fairly priced. But, outside those assumptions, we also have a number of cases where we attribute value to what we think is substantial unpriced upside should Novartis continue to execute well on a number of the new technology platforms that it's rolling out and where we think it's early to market and have substantial competitive advantages. And I'd reference gene therapy is one of those unpriced options where we think we're able to capture future upside should it execute as we expect.



Important Information: Units in the fund(s) referred to herein are issued by Magellan Asset Management Limited ABN 31 120 593 946, AFS Licence No. 304 301 ("Magellan"). This material has been delivered to you to provide information regarding Magellan and has been prepared for informational purposes only and must not be construed as investment advice or as an investment recommendation. This material does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful. This material does not take into account your investment objectives, financial situation or particular needs. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. A copy of the relevant PDS relating to a Magellan financial product or service may be obtained by calling +61 2 9235 4888 or by visiting [www.magellangroup.com.au](http://www.magellangroup.com.au). Statements contained in this material that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of Magellan. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. This material may contain "forward-looking statements". Actual events or results or the actual performance of a Magellan financial product or service may differ materially from those reflected or contemplated in such forward-looking statements. This material may include data, research and other information from third party sources. Magellan makes no guarantee that such information is accurate, complete or timely and does not provide any warranties regarding results obtained from its use. No representation or warranty is made with respect to the accuracy or completeness of any of the information contained in this material. Magellan will not be responsible or liable for any losses arising from your use or reliance upon any part of the information contained in this material. Any trademarks, logos, and service marks contained herein may be the registered and unregistered trademarks of their respective owners. Nothing contained herein should be construed as granting by implication, or otherwise, any licence or right to use any trademark displayed without the written permission of the owner. No part of this material may be reproduced or disclosed, in whole or in part, without the prior written consent of Magellan.